

Application for Recognition of ISPOR Italy-Rome Chapter

January 2, 2014

To: ISPOR Board of Directors
505 Lawrence Square Blvd South
Lawrenceville, NJ 08648, USA

From: Prof. Francesco Saverio Mennini, MSc
Professor of Health Economics, Università Tor Vergata and
Professor of Economics and Health Care Planning
Università La Sapienza
Rome, Italy
E-mail: mennini@uniroma2.it

Dear Members of ISPOR Board of Directors,

This letter is a formal request to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for the recognition of ISPOR Chapter in Italy, named ISPOR Italy - Rome Chapter.

The prospective Chapter's Executive Committee is composed of researchers and practitioners with various backgrounds; it includes health economists, clinicians, pharmacologists, hospital pharmacists, as well as experts from academia, research centers, and health care organizations.

Members of the Executive Committee play a key role in the research field and many of them have been directly involved in the activities of regulatory authorities and third party payers. The members share ISPOR mission and vision, and have been involved with ISPOR as reviewers and speakers at ISPOR congresses.

The mission of the prospective ISPOR Italy-Rome Chapter is to apply ISPOR values in Italy by enhancing a rigorous application of health economics and outcome research in decision making and encouraging fruitful collaboration between all actors interested in improving the allocative efficiency of scarce resources. The main focus of ISPOR Italy-Rome Chapter is to strengthen HTA and economic assessment usage in order to take rational decision affecting health policy in our country. The Chapter's headquarters is located in Rome.

I appreciate ISPOR's consideration for the recognition of ISPOR Italy-Rome Chapter.
Sincerely yours,



Prof. Francesco Saverio Mennini, MSc
Professor of Health Economics, Università Tor Vergata and
Professor of Economics and Health Care Planning, Università La Sapienza, Rome, Italy
Visiting Professor, Institute of Leadership and Management, Kingston University, London, UK

Application

Enclosed are the following documents:

- 1) Evidence of existence of the organization
- 2) Constitution of the ISPOR Italy-Rome Chapter
- 3) A list of ISPOR Italy-Rome Chapter members and ISPOR members
- 4) A list of ISPOR Italy-Rome Chapter elected officials
- 5) A summary of upcoming activities for the ISPOR Italy-Rome Chapter

Permanent address, phone number, and fax of the ISPOR Italy-Rome Chapter

ISPOR Italy-Rome Chapter Office
Università Tor Vergata, CEIS-Economic Evaluation and HTA (EEHTA)
via Columbia 2, 00133 Rome, Italy
Telephone: +39 06 7259 5642
Fax: +39 02 89098927
Email: lanati@maprovider.com

Application

ISPOR ITALY- ROME CHAPTER CONSTITUTION

Article 1 : Name

The name of this organization is the International Society for Pharmacoeconomics and Outcomes Research Italy Regional Chapter, herein referred to as ISPOR Italy-Rome Chapter. The Chapter is independent, with no link to politics, religion, confession and no profit (mandatory according to Italian law).

Article 2 : Mission

The mission of the ISPOR Italy-Rome Chapter is to:

- Improve efficacy, effectiveness and fairness of health care system to improve health.
- Build, develop, and ensure ISPOR Italy-Rome Chapter membership representation from health care researchers, health care practitioners, and health care decision-makers who are interested in pharmacoeconomics and outcomes research.
- Provide an environment where health care researchers, health care practitioners, and health care decision-makers interested in pharmacoeconomics and outcomes research can share knowledge at a country or regional level.
- Serve as a bridge in bringing together local researchers, health care practitioners, and decision-makers interested in pharmacoeconomics as well as members of the pharmaceutical medical device/diagnostics industry, health-related organizations, and academia.
- Act as a resource at a local level for individuals interested in pharmacoeconomics and outcomes research and its use in health care decisions.
- Provide an opportunity for Chapter members to become more familiar with the activities of ISPOR as well as participate in its activities.
- Develop, implement and sustain ISPOR Italy-Rome Chapter.
- Serve as consultants/peer reviewers in the design of or assist in the development of pharmacoeconomics, health outcomes research and health technology assessment at a local level.
- Disseminate local pharmacoeconomics, health outcomes research and health technology assessment information to stakeholders.
- Organize seminars, studies, researched, congresses, conferences, educational and informational courses, debates, meetings, scientific publications.
- Collaborate with public and private institutions, on top to other voluntary groups working on the country, as well as foreign institutions having the same mission, with the objective also to favor experiences exchange.

Article 3 : Affiliation

This ISPOR Italy-Rome Chapter maintains affiliation as a component chapter of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Article 4 : Membership

- Membership is open to any individual working within the country or region interested in the ISPOR Italy-Rome Chapter and who support the mission of ISPOR Italy-Rome Chapter.
- The ISPOR Italy-Rome Chapter is made of ordinary members; it is not allowed the status of temporary member.
- All members have the same rights and duties, based on the kind of role they have in the ISPOR Italy-Rome Chapter.

Application

- All members have to respect the following Constitution, decisions taken by the Executive Committee according to the same constitution.
- Membership is lost just in case of death, recession or exclusion.
- Member can recess from the ISPOR Italy-Rome Chapter, with a simple written communication to the Executive Committee.
- Member can be excluded for severe reasons and because violates the duties fixed by this Constitution, the decisions taken by the Executive Committee. The exclusion is resolved, with written and motivated decision, by the Executive Committee, after auditing the interested member, having a contradictory.
- The resolved or excluded members cannot ask for returning back the ISPOR Italy-Rome Chapter membership fee, and don't have any right to the ISPOR Italy-Rome Chapter assets.

Article 5 : Procedures

- ISPOR Italy-Rome Chapter is governed by this constitution.
- ISPOR Italy-Rome Chapter is a recognized organization in the country and complies with local government policies. ISPOR Italy-Rome Chapter holds at least 1 general meeting during the year. Minutes of meetings must be taken. Minutes must be provided to the ISPOR Board of Directors upon request.
- Any member of the ISPOR Italy-Rome Chapter may suggest a constitutional amendment. Procedures for amending this Constitution are outlined in Article 9.

Article 6 : Chapter Leadership

1. The leadership of the ISPOR Italy-Rome Chapter is the Executive Committee.
2. The leadership must have their professional post within Italy.
3. The Executive Committee consists of the following elected members: President, President-elect, Past President, Secretary, Treasurer, at least five Directors and Coordinator of the Scientific Committee. Members of the Executive Committee should represent diverse geographic locations and work environments. To facilitate the objectives of the Society and the Regional Chapter the President should be a health care decision-maker or an active researcher in the field of economics /outcomes research, at least for the first 5 years of the Chapter. An active researcher is an ISPOR Regional Chapter member who has published research or policy articles within the last several as is demonstrated in his/her curriculum vitae. The President is limited to two consecutive terms (up to six years) to allow the Regional Chapter continuity in leadership in its initial years. President-elect / President / Past President are limited to one term. ISPOR Italy-Rome Chapter members elect the members of the Executive Committee. Elections are to be held according to the rules and procedures outlined in Article 8.
4. ISPOR Italy-Rome Chapter members elect the members of the Executive Committee. Elections are to be held according to the rules and procedures outlined in Article 8.
5. At least three members of the Executive Committee are ISPOR members.
6. Members of the ISPOR Italy-Rome Chapter Executive Committee hold their respective positions for a term of three years, or for the remainder of a term when filling a vacancy. The position of Director or Secretary and Treasurer can serve a second term if re-elected by members of ISPOR Italy-Rome Chapter.
7. The Executive Committee oversees and supports activities of the Chapter. The duties and responsibilities of the Executive Committee should be as defined in Article 7.
8. The Executive Committee's responsibilities include upholding the mission of the ISPOR Italy-Rome Chapter as defined in Article 2.
9. Executive Committee meetings are held as needed. Minutes of meetings must be taken. Minutes must be provided to the ISPOR Board of Directors upon request.
10. The ISPOR Italy-Rome Chapter Executive Committee has the right to make decisions according to ISPOR Italy-Rome Chapter Constitution.

Application

11. In addition to the Executive Committee, ISPOR Italy-Rome Chapter will benefit from a Scientific Committee Coordinator, elected by the Scientific Committee. The Scientific Committee Coordinator is a member of the Executive Committee. The Scientific Committee members are leading the related subgroups, focused on specific scientific topics.

Article 7: Duties of Executive Committee

President

The President of ISPOR Italy-Rome Chapter:

- Takes office after a term as President-elect and holds this position for a term of up to three years;
- Oversees ISPOR Italy-Rome Chapter activities;
- Conducts and presides over all meetings of ISPOR Italy-Rome Chapter ;
- Represents ISPOR Italy-Rome Chapter when called upon to do so;
- Provides an annual report of activities and financial transactions including a list of current ISPOR Italy-Rome Chapter members to the ISPOR Board of Directors.

The office is open to any member of ISPOR Italy-Rome Chapter, in accordance with the requirements outlined in Article 6.

President-elect

The President-elect of ISPOR Italy-Rome Chapter:

- Holds this position for a term of up to three years as President-elect, and at the end of the term as President-elect becomes President;
- Conducts and presides over all meetings of ISPOR Italy-Rome Chapter in the absence of the President
- Assists the President with the responsibilities and duties as necessary.

The office is open to any member of ISPOR Italy-Rome Chapter, in accordance with the requirements outlined in Article 6.

Past President

The Past President of the ISPOR Italy-Rome Chapter:

- Holds this position for a term of up to three years after serving as President;
- Conducts and presides over all meetings of ISPOR Italy-Rome Chapter in the absence of the President/President-elect;
- Assists the President with the responsibilities and duties as necessary.

The office is open to any member of ISPOR Italy-Rome Chapter, in accordance with the requirements outlined in Article 6.

Secretary

The Secretary of the ISPOR Italy-Rome Chapter:

- Records the minutes of ISPOR Italy-Rome Chapter meetings. An official copy of the minutes should be kept in the ISPOR Italy-Rome Chapter records and a copy emailed to: RegionalChapter@ispor.org;
- Handles ISPOR Italy-Rome Chapter correspondence as necessary;
- Keeps and maintains the ISPOR Italy-Rome Chapter records;
- Keeps and maintains ISPOR Italy-Rome Chapter membership list;
- Track record of all monies received and spent by the secretary of ISPOR Italy-Rome Chapter, reporting it to the Treasurer;
- Assists the board members in the preparation and coordination of ISPOR Italy-Rome Chapter meetings;
- Assists in external communication: developing content for the website, newsletters, public presentations, and articles as appropriate.

The office is open to any member of ISPOR Italy-Rome Chapter, in accordance with the requirements outlined in Article 6.

Application

Treasurer

The Treasurer of the ISPOR Italy-Rome Chapter:

- Is responsible for any financial transactions of ISPOR Italy-Rome Chapter ;
- Keeps and maintains the ISPOR Italy-Rome Chapter records;
- Is responsible for the record of all monies received and spent by ISPOR Italy-Rome Chapter ;
- Reports the financial status of ISPOR Italy-Rome Chapter at meetings;
- Assists the President in the preparation of an annual budget and the official closure;
- Oversees the financial activities of ISPOR Italy-Rome Chapter, together with the President.

The office is open to any member of ISPOR Italy-Rome Chapter.

Directors

- A Director of ISPOR Italy-Rome Chapter:
- Initiates activities of the Chapter;
- Perform duties as assigned by the Executive Committee;
- Work with and manage external consultants.

The office is open to any member of ISPOR Italy-Rome Chapter, in accordance with the requirements outlined in Article 6.

In particular, the Executive Committee:

- Acts to fulfill the mission of ISPOR Italy-Rome Chapter;
- Resolves about the admission of new members;
- Resolves about the amount of the annual membership fee, and of the minimum contribution;
- Prepares annual budget both final and preventive, based on the treasurer's suggestion;
- Resolves about the opportunity to receive donations;
- Decides about providing ISPOR Italy-Rome Chapter patronage and guidance;
- Resolves about purchasing or sales of any assets;
- Funds scientific grants, and promotes publications;
- Proposes to members any possible change to the current Constitution.

The Scientific Committee:

- Is responsible for scientific development of ISPOR Italy-Rome Chapter;
- Is made of group of experts elected by Chapter members, to lead scientific research;
- Is chaired by a coordinator, who is a member of the ISPOR Italy-Rome Chapter Executive Committee and is responsible for the interaction on scientific issues with both ISPOR and the Executive Committee;
- The office in the scientific committee, for a coordinator and a member is open to any member of ISPOR Italy-Rome Chapter, in accordance with the requirements outlined in Article 6.

Article 8 : Election Procedures

1. The members of ISPOR Italy-Rome Chapter elect the members of the Executive Committee. Each ISPOR Italy-Rome Chapter member has one vote.
2. The Executive Committee incumbent members select at least two ISPOR Italy-Rome Chapter members from diverse work environment and geographic location for submission to the Nomination Committee.
3. The Nomination Committee solicits candidates for the positions of President-elect, Secretary/Treasurer, Directors and Scientific Committee members by notifying all ISPOR Italy-Rome Chapter members electronically or by postal mail, prior to the end of the term of the incumbent.

Application

4. The Nominations Committee selects at least two candidates for each position ensuring that the selected slate complements the incumbent Executive Committee with respect to education, professional interest, work environment, geographic location, and gender.
5. If selected for audit, The Nominations Committee will provide the ISPOR Board of Directors with evidence that the elections were conducted in a fair manner.
6. All elected positions must receive a majority vote (>50% of votes received).
7. The incumbent ISPOR Italy-Rome Chapter President informs the ISPOR Board of Directors of the newly elected Executive Committee members via: RegionalChapter@ispor.org.
8. Unless initiated by a decision of the President, or by any member of the Executive Committee regarding their elected term, an Executive Committee member holds their position until the end of the defined term. Executive Committee members should not be required to step down by any member of the ISPOR Italy-Rome Chapter. If there is a dispute that needs further resolution, a petition must be formally submitted to the ISPOR Board of Directors via regionalchapter@ispor.org.
9. If a change in leadership occurs outside the parameters outlined in this constitution, the Chapter and / or new leadership are subject to disbandment by ISPOR Board of Directors.

Article 9: Amendments

1. Any member or officer of ISPOR Italy-Rome Chapter may propose constitutional amendments.
2. A proposed amendment to this or a new Constitution should become binding after receiving a two-thirds majority of the total voting membership of ISPOR Italy-Rome Chapter.

Article 10: Indemnification

ISPOR Italy-Rome Chapter will indemnify ISPOR from liability for injury or damage, cost or expense resulting from or which arises out of or in connection with the use by ISPOR Italy-Rome Chapter of the ISPOR name, logo, or arising from the relationship or affiliation between the parties.

ISPOR Italy-Rome Chapter Members and ISPOR Members

First and last Name	ISPOR ID	Position	Organization	City
Giorgio Colombo, MD	6217	Scientific Director	S.A.V.E. Studi Analisi Valutazioni Economiche	Milan
Elena Lanati, PharmD	20646	CEO and Managing Director	3P Solution	Milan
Francesco Saverio Mennini, MSc	18617	Professor of Health Economics	CEIS Economic Evaluation and HTA (EEHTA), Faculty of Economics, University Tor Vergata, Roma and Kingston University, London, UK.	Rome
Alberto Migliore, MD	22675	Director	Chief Rheumatology Unit, San Pietro Hospital	Rome
Tomaso Piaggio, PharmD	19525	Researcher	Eli Lilly and Company	Rome
Paolo Daniele Siviero, PhD	16738	Head of Economic Strategy and Pharmaceutical policy	AIFA	Rome

ISPOR Italy-Rome Chapter Members

First and last Name	Degree	ISPOR Position	Organization	City
Francesco Saverio Mennini	MD	President	Professor of Health Economics Research Director, CEIS - Economic Evaluation and HTA (EEHTA), Faculty of Economics, University Tor Vergata, Roma and Kingston University, London, UK.	Rome
Alberto Migliore	MD	President Elected	Director, Chief Rheumatology Unit San Pietro Hospital	Rome
Elena Paola Lanati	PharmD	Secretary	CEO and Managing Director 3P Solution	Milano
Tomaso Piaggio	PharmD	Treasurer	Researcher Eli Lilly and Company	Rome
Pier Luigi Canonico	MD	Director	Past President of Italian Society of Pharmacology, Director of Drug Science Department, Università del Piemonte Orientale	Novara
Americo Cicchetti, MD	MD	Director	Vice President SIHTA, member of Price&Reimbursement Committee at National Drug Agency (AIFA), Full Professor of Economics at Università	Rome/Milano

Application

			Cattolica del Sacro Cuore, Milan	
Andrea Messori, PharmD	PharmD	Director	Secretary of Toscana Association of Hospital Pharmacist, former member of Price&Reimbursement Committee at National Drug Agency (AIFA)	Firenze

Application

**Summary of the short and long-term activities of
ISPOR Italy-Rome Chapter**

The ISPOR Italy-Rome Chapter Executive Committee decided on the following activities plan:

Short term: 1-year

- Develop scientific committee led by 2 Chapter members focusing on a specific area of research;
- Promote participation and involvement in ISPOR activities among ISPOR Italy-Rome Chapter members;
- Publication of articles in ISPOR ViHRI;
- Disseminate information about ISPOR publications and guidelines;
- Update information on Italy on ISPOR website: (<http://www.ispor.org/htaroadmaps/italy.asp>), with a focus on relationships between central and regional governments;
- Participate in initiatives aimed to illustrate current pharmaceutical policy in Italy;
- Assess impact risk-sharing agreements in collaboration with regulatory authorities and third party payers;
- Connect and collaborate with other Italian scientific societies (e.g. Italian Association of Health Economics (AIES), Italian Society of HTA (SIHTA)) to present activities and research results of the ISPOR Italy-Rome Chapter at their regional congresses and to increase awareness on ISPOR activities and encourage membership;
- Develop communication tools and membership programs: contribute to ISPOR Italy website, ISPOR LinkedIn, newsletter.

Long term: 2-3 years

- Collaborate on projects in Italy focused on QALYs;
- Macro analysis of the role in decision making and estimation of loss of productivity costs in Italy for a pool of diseases.

Further activities for discussion:

- Develop slides on pharmacoeconomics and outcomes research to be used for one-on-one discussions;
- Develop educational activities focused on pharmacoeconomics and outcomes research;
- Disseminate local pharmacoeconomics and outcomes research information;
- Organization of trainings and meetings on topics related to pharmacoeconomics and health outcomes research addressed to all ISPOR members;
- Development of documents and publications on current status of pharmacoeconomics and outcomes research in Italy;
- Organization of promotional event to present ISPOR Italy-Rome Chapter and its activities at the Italian Senate;
- Publication of articles in Italian scientific journals to promote activities of ISPOR Italy-Rome Chapter;
- Media involvement to understand and disseminate information about ISPOR and the Chapter: promote results from the research led by this and other ISPOR Chapters in Europe.

Application

Note on Italy

Key data:

- Italy is a country of 59,4 million people (Istat 2011 data-National data agency, of which 4,9 millions of regular foreign people)
- % of GDP covered by the health care system in 2011: 7,1% (113 billions €)
- %of GDP covered by citizens for health: 1,8% in 2011 (28 billions €)
- 3,7 hospital beds/1000 people, sixth lowest level in EU
- Current health care systems is based on:
 - Centralized governance within the Ministry of Health
 - Decentralized HC budget managed by the 21 Regions, which implies strong regionalization and differences across Regions in terms of care and spending
- Health care overspending vs. budget from Regions in 2010: 3,1 billions €

A handwritten signature in black ink, appearing to be 'P. R.', written over a horizontal line.

Memorandum
Application for ISPOR Italy-Rome Chapter

January 2, 2014

To: ISPOR Board of Directors
505 Lawrence Square Blvd South
Lawrenceville, NJ 08648, USA

From: From: Prof. Francesco Saverio Mennini, MSc
Professor of Health Economics, Università Tor Vergata and
Professor of Economics and Health Care Planning
Università La Sapienza
Rome, Italy
E-mail: mennini@uniroma2.it

Dear Members of ISPOR Board of Directors,

The following memorandum addresses the request for the recognition of ISPOR Italy-Rome Chapter that is being submitted with this letter.

ISPOR has been approached by two groups of experts in the field of pharmacoeconomics and outcomes research from Italy simultaneously interested in establishing an ISPOR Regional Chapter in Italy. Efforts were made to encourage submission of a joint application requesting recognition of one ISPOR Regional Chapter in Italy. However, at the end both groups decided to file separate applications. In order to provide opportunity for establishing multiple Chapters in Italy, it was recommended by ISPOR that Chapters' names reflect the city name, where a Chapter's office is located.

Hence, submitted for your consideration is application for ISPOR Italy-Rome Chapter.

With kind regards,



Prof. Francesco Saverio Mennini, MSc
Professor of Health Economics, Università Tor Vergata and
Professor of Economics and Health Care Planning, Università La Sapienza, Rome, Italy
Visiting Professor, Institute of Leadership and Management, Kingston University, London, UK

Curriculum Vitae

Prof. Francesco Saverio Mennini

Education and Awards

- **Visiting Professor**, Kingston University, London, UK (from 2011)
- **Professor**, Health Economics and Political Economics, University of Rome “Tor Vergata” (from 2004 – Faculty of Economics and Faculty of Science)
- **Professor** Health Economics, University of Rome “La Sapienza” (from 2008 – Department of Statistics)
- **Confirmed Researcher** at the Faculty of Economics of the University of Rome “Tor Vergata” (2004)
- **Research Director** centre for Economic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics University of Rome “Tor Vergata”.
- 2008-2012 -Chair of the Scientific Committee of the European Health Economics Association (ECHE).
- Chair of the Scientific Committee for ECHE Roma 2008, European Conference on Health Economics, European Health Economics Association, Roma 23-26 July 2008.
- Adviser to the Technical Consensus Meeting on Headache Outcome Measures - World Health Organization Project: “Global Campaign to Reduce the Burden of Headache Worldwide”, WHO in collaboration with Leading NGOs.
- referee of Journal of Headache and Pain (from 2006).
- referee of Vaccine (from 2008).
- referee of Health Policy (from 2009).
- referee of Journal of Occupational and Environmental Medicine (from 2011)
- member of different Scientific Board concerning Pharmacoeconomics Analyses and Outcome research related topics.

Research Activities and Projects

- Scientific Board “Design for a Set of Italian Health Indicators”, project financed by Ministry of Health.(2003-2004).
- Member of the Scientific Committee of Centre for Technology Assessment in Public Health (CTAPH), Region Lazio Health Agency (2004-2007).
- Scientific Board “Organizational Plan for S. Camillo Forlanini Hospital (Rome)”.(2003-2004)
- Economic Evaluation of Screening Programmes for Breast Cancer in Italy, project financed by the Agency for Public Health of Region Lazio (ASP Lazio) 2005-2006.
- Economic Evaluation of Screening Programmes for Colorectal Cancer in Italy, project financed by the Agency for Public Health of Region Lazio (ASP Lazio) 2005-2006.
- “Experimental cost-efficacy evaluation of guidelines for the screening, early diagnosis and multidisciplinary treatment of colorectal cancer“, project financed by Ministry of Health (Regional Health Services Agency - ASSR) 2005-2007.
- Health Economist Advisor for the “Technical Consensus Meeting on Headache Outcomes Measures” into the project “Global Campaign to Reduce the Burden of Headache Worldwide” (organised by WHO), 2006, 2007,2008 and 2009.
- Economic Evaluation of Screening Programmes for Colorectal Cancer, project financed by the Agency for Public Health of Region Abruzzo (ASR Abruzzo) 2009-2011.
- Scientific Coordinator of the project “The definitions of QoL for Italy”, project organised by AIES (Italian Health Economics Association), 2010-2012.
- Scientific Coordinator of "MEDICAL DEVICES and HOSPITALIZATION COSTS: The DETERMINATION of TARIFFS for IMPROVED REGIONAL and Corporate PROGRAMMING.", research project financed by Ministry of Health, 2011-2013.
- Scientific Coordinator of TRAINING COURSE: THE DISSEMINATION AND MANAGEMENT OF MEDICAL DEVICES AT THE ENTERPRISE LEVEL. research project financed by Ministry of Health, 2011-2013.
- Scientific Coordinator of dell’Unità Operativa “Programmazione Economico Finanziaria”, all’interno del progetto finalizzato INAPPROPRIATEZZA DELL’USO DEI FARMACI NELL’ANZIANO: RILEVANZA IN CLINICA E IN FARMACOECONOMIA., finanziato dal Ministero della Salute, (2005-2008).
- Scientific Coordinator of del Progetto di Ricerca “Economic evaluation of screening programs against colorectal cancer: indirect evidence of long-term and financial sustainability in the context of regional programming” applied research project financed by Health Agency Region Abruzzo. (2008-2010).
- Member, as expert of Health Economics, of the Technical Commission on control of health expenditure for HIV drugs – Region Lazio (from 2010)
- Member, as expert of Health Economics, of the Technical Commission on control of health expenditure for HCV drugs – Region Lazio (from 2012)
- Member of the Advisory Board, as expert of Health Economics, for the project "Unhealthy Health System - Promoting integrity in the health service and implementino check and balance evaluation", assigned to Transparency International Italy (TI-It) from EU Commission DG-Home Affairs.

Papers and Monography published or accepted for publication (peer reviewed journals)

- Transparency or Proper Study Valuation Procedures Missed?, Favato, G.; Baio, G.; Capone, A.; Marcellusi, A.; Costa, S.; Garganese, G.; Picardo, M.; Drummond, M.; Jonsson, B.; Scambia, G.; Zweifel, P.; Mennini, F.S., *Medical Care*. 51(4):374-378, April 2013. doi: 10.1097/MLR.0b013e31828a6a1e
- Economic Burden of Human Papillomavirus-Related Diseases in Italy, Mennini, F.S., et al., *PLOS ONE*, November 2012 | Volume 7 | Issue 11 | e49699.
- NOVEL HEALTH ECONOMIC EVALUATION OF A VACCINATION STRATEGY TO PREVENT HPV-RELATED DISEASES: THE BEST STUDY, Mennini, F.S., et al., *Medical Care*, 2012.50(12):1076-1085, December 2012. doi: 10.1097/MLR.0b013e318269e06d
- Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study. Mennini, F.S., et al., *BMJ Open*.2012;2:e000736. doi:10.1136/bmjopen-2011-000736. 2012.
- The time trade-off procedure to measure health utilities loss with HPV-induced diseases: an Italian multicenter pilot study - Mennini, F.S., et al., *Clinical Therapeutics - CLITHE* Vol. 33, Issue 8, Pages 1084-1095.e4 - 2011.
- Multiple Sclerosis in Italy: cost-of-illness study, Mennini, F.S., et al., *Neurological Sciences*, Vol. 32, Num 5, Springer eds., October 2011.
- Economics of Headache, chapter 6, Mennini, F.S., et al., in Paolo Martelletti, Timothy J. Steiner (eds.), *Handbook of Headache*, DOI 10.1007/978-88-470-1700-9_6, Springer Science+Business Media, LLC 2011 *Handbook of Headache*, Springer, 2011.
- BAYESIAN MODELLING ASSESSING THE EFFECTIVENESS OF A VACCINATION STRATEGY TO PREVENT HPV-RELATED DISEASES: THE BEST STUDY, Mennini, F.S., et al., *Value in Health*, May 2011.
- Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study, Mennini, F.S., et al., *Current Medical Research & Opinion* Vol. 27, No. 3, 2011, 569–578, 2011.
- Extending influenza vaccination to individuals aged 50-64. A budget impact analysis. Mennini, F.S., et al., *International Journal of Technology Assessment in Health Care*, Volume 26 , Issue 03 , Jul 2010 , pp 288-293, 2010.
- Hospital Costs Incurred by the Italian National Health Service for Invasive Cervical Cancer, Mennini, F.S., et al., *Gynecologic Oncology* 119 (2010) 243–249, 2010.
- Improving care through health economics analyses: Cost of illness and headache (general disease costing principles), Mennini, F.S., et al., in *Headache Care, Research, and Education Worldwide* (edited by J. Olesen and N. Ramadan), Session III , chapter 12 (83-99), Oxford University Press, 2010.
- Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to Regional healthcare providers, Mennini, F.S., et al., *Annals of Oncology*, 2010, 10.1093/annonc/mdq097.
- Rapid responses to: “Letter to the Editor”, Mennini, F.S., et al., *Vaccine* 27 (2009) 7238–7239, 2009
- Anti-HPV Vaccination in Italy: A Review of Recent Economic Data for Italy. Mennini, F.S., et al., *Vaccine*, ISSN: 0264-410X. Ms. Ref. No.: JVAC-D-08-01335R1.

- The Cervical Cancer Cost Containment (C3A) Study: a cross linking data-based analysis designed to estimate direct expenses induced by the management of early stage versus locally advanced cervical cancer in Italy. Mennini, F.S., et al., *Annals Academy of Medicine*, June 2009, Vol. 38 (Suppl) No.6.
- Health and Economic Impact associated with a quadrivalent HPV vaccine in Italy. Mennini, F.S., et al., *Gynecologic Oncology*, Volume 112, Issue 2, Pages 291-438 (February 2009), Elsevier.
- Improving Care Through Health Economics Analyses: Cost of Illness and Headache, Mennini, F.S., et al., *Journal of Headache and Pain*, DOI 10.1007/s10194-008-0051-9, 2008.
- Comparison between product characteristics and decision analysis supporting decision-makers in public health-related choices: a study model applied to anti-HPV vaccines. Mennini, F.S., et al., January 1, 2008. Available at Social Science Research Network (SSRN): <http://ssrn.com/=1080089>
- Costs Analysis of Breast Cancer Screening in Italy, (Mennini, F.S., et al.). *The European Journal of Health Economics*, 7, suppl. 1, S34, 2006.
- "A One-Year Economic Evaluation of Botulinum Toxin Type A Treatment of Chronic Tension-type Headaches: Part II", (Mennini, F.S., et al.), *Journal of Headache and Pain*, 2005.
- "A One-Year Economic Evaluation of Botulinum Toxin Type A Treatment of Chronic Tension-type Headaches: Part I", (Mennini, F.S., et al.), *Journal of Headache and Pain*, 2005.
- "The Welfare States in a United Europe", (Mennini, F.S., et al.), *European Political Economic Review (EPER)*, Vol.1, Num.1, 2003.
- "General Disease Costing Principles", (Mennini, F.S., et al.), *Journal of Headache and Pain*, Vol. 4, Issue s01, pp s55-s58, 2003.
- "European Discrepancies in Prices, Expenditure and Utilisation of Antimigraine Medicines", (Mennini, F.S., et al.), *Fourth European Conference on Health Economics, Proceedings, The European Journal of Health Economics*, Vol. 3, supplement, pag. 77, Springer 2002.
- "Size and Trends of Pharmaceutical Market in Italy (1980-1997)", (Mennini, F.S., et al.), Abstract Book "The Economics of Health, Within and Beyond Health Care", IHEA Third International Conference, York July 2001.
- "Cost Effectiveness of Anaesthesia/Analgesia", (Mennini, F.S., et al.), in *Regional Anaesthesia, Analgesia and Pain Management*, M.Tiengo, V.A.Paladini, N.Rawal (Eds), ed. Springer, 1998
- "Piano di Intervento Sanitario nelle Zone Rurali dell'America Latina", (Mennini, F.S., et al.), *Proceedings dell'8ième Congrès Annuel de l'Association Latine pour l'Analyse des Systèmes de Santé su "La Reforma de los Modelos Sanitarios, la Definición del Producto y las Necesidades de Gestión"*.19-21 giugno, Granada, Spagna, pp. 92-9, 1997.
- "I Costi di un Progetto di Prevenzione delle Malattie Oftalmiche", (Mennini, F.S., et al.), *Proceedings dell'8ième Congrès Annuel de l'Association Latine pour l'Analyse des Systèmes de Santé su "La Reforma de los Modelos Sanitarios, la Definición del Producto y las Necesidades de Gestión"*.19-21 giugno, Granada, Spagna, pp. 298-305, 1997.
- "New Payment System in the Italian National Health Service", (Mennini, F.S., et al.), *Proceedings of the Sixth International Conference on System Science in Health Care*.Barcelona, September 16-17. Neuherberg, GSF-Forschungszentrum, pp. 156-162, 1996.
- "Italian Pharmaceutical Industries: Perspectives, Problems, Development and Data Analysis", (Mennini, F.S.,

Papers presented at the following conferences (most recent)

- 2012 A Marcellusi, L Gitto, P Giannantoni, FS Mennini. Social impact of Adalimumab in the Italian perspective. European Conference of Health Economics (ECHE). Berlin 18-21 July 2012. Oral presentation
- 2012 A Marcellusi, P Giannantoni. Bayesian modelling assessing the effectiveness of a vaccination strategy to prevent hpv-related diseases European Population Conference (EPC 2012), Stockholm, Sweden, 13 -16 June 2012. Poster presentation
- 2012 A Marcellusi, L Gitto, P Giannantoni, G Favato, FS Mennini. Comprehensive Value Estimation Of Adalimumab-Based Treatments: Covet Study. European Conference of Health Economics (ECHE). Berlin 18-21 July 2012.
- 2012 A Marcellusi, L Gitto, P Giannantoni, G Favato, FS Mennini. Comprehensive Value Estimation Of Adalimumab-Based Treatments: Covet Study. European Health Management Association (EHMA) congress. Bern 13-15 June 2012.
- 2012 Marcellusi A, Bansback N, Rao S, Cifaldi M, Gitto L, Giannantoni P, Russo S, Mennini FS. Economic Evaluation of Adalimumab vs other biologic treatments for moderate to severe psoriatic arthritis in Italy. ISPOR 15th Annual European Congress, 3-7 November 2012 ICC Berlin, Berlin, Germany.
- 2012 Marcellusi A, Bansback N, Rao S, Cifaldi M, Gitto L, Giannantoni P, Russo S, Mennini FS. Economic Evaluation of Adalimumab vs other biologic treatments for moderate to severe psoriatic arthritis in Italy. 49° National Conference of the Società Italiana di Reumatologia (SIR), 21-24 November 2012 MiCo Milano Congressi, Milan, Italy.
- 2012 A Marcellusi, M Botteman, SA Rao, M Cifaldi, Solem CW, L Gitto, P Giannantoni, FS Mennini. Cost effectiveness of Adalimumab vs. Golimumab and placebo in Ankylosing Spondylitis in Italy. ISPOR 15th Annual European Congress, 3-7 November 2012 ICC Berlin, Berlin, Germany.
- 2012 A Marcellusi, M Botteman, SA Rao, M Cifaldi, Solem CW, L Gitto, P Giannantoni, FS Mennini. Cost effectiveness of Adalimumab vs. Golimumab and placebo in Ankylosing Spondylitis in Italy. I49° National Conference of the Società Italiana di Reumatologia (SIR), 21-24 November 2012 MiCo Milano Congressi, Milan, Italy.
- 2012 A Benedict, T Kongnakorn, JW Shaw, A Marcellusi, DJ Vanness, L Gitto, P Giannantoni, MA Cifaldi, G Attinà, FS Mennini. Economic Evaluation of Adalimumab for the Treatment of Early- and Late-Stage Rheumatoid Arthritis in Italy. ISPOR 15th Annual European Congress, 3-7 November 2012 ICC Berlin, Berlin, Germany.
- 2012 A Benedict, T Kongnakorn, JW Shaw, A Marcellusi, DJ Vanness, L Gitto, P Giannantoni, MA Cifaldi, G Attinà, FS Mennini. Economic Evaluation of Adalimumab for the Treatment of Early- and Late-Stage Rheumatoid Arthritis in Italy. 49° National Conference of the Società Italiana di Reumatologia (SIR), 21-24 November 2012 MiCo Milano Congressi, Milan, Italy.
- 2012 A Benedict, T Kongnakorn, JW Shaw, A Marcellusi, DJ Vanness, L Gitto, P Giannantoni, MA Cifaldi, G Attinà, FS Mennini. Economic Evaluation of Adalimumab for the Treatment of Early- and Late-Stage Rheumatoid Arthritis in Italy. ACR/ARHP Annual Meeting, 10-14 November 2012 Walter E. Washington Convention Center, Washington D.C., Unites States.
- 2012 A Marcellusi, L Gitto, P Giannantoni, G. Attinà, J. Chao, FS Mennini. Economic Evaluation of Adalimumab for the maintenance of remission in patients with Crohn's disease in Italy. Associazione Italiana di Economia Sanitaria (AIES) 17° National Conference, 15-16 November 2012 Università Cattolica del Sacro Cuore, Rome, Italy
- 2012 A Marcellusi, L Gitto, P Giannantoni, G Attinà, M Sundaram, FS Mennini. Economic Evaluation of Biologic treatments for Moderate to Severe Psoriasis in Italy. ISPOR 15th Annual European Congress, 3-7 November 2012 ICC Berlin, Berlin, Germany.
- Bayesian Modelling Assessing the Effectiveness of a Vaccination Strategy to Prevent HPV-Related Diseases: the BEST study. iHEA (International Health Economics Association) Congress, July 10-13, 2011, Toronto, CAN.

- Valutazione economica dei programmi di screening contro il Cancro al Colon Retto: evidenze indirette dilungo periodo e sostenibilità finanziaria in un'ottica di programmazione regionale. XVI Convegno Nazionale Associazione Italiana di Economia Sanitaria. Napoli, 29-30 Settembre 2011.
- Bayesian Modelling Assessing the Effectiveness of a Vaccination Strategy to Prevent HPV-Related Diseases: the BEST study. XVI Convegno Nazionale Associazione Italiana di Economia Sanitaria. Napoli, 29-30 Settembre 2011.
- The GIOVE study: Governance of preventive health Intervention and On time Verification of its Efficiency in a Region of Southern Italy. XVI Convegno Nazionale Associazione Italiana di Economia Sanitaria. Napoli, 29-30 Settembre 2011.
- Bayesian Modelling Assessing the Effectiveness of a Vaccination Strategy to Prevent HPV-Related Diseases: the BEST study. ISPOR 16th Annual International Meeting, May 21-25, 2011, Baltimore, MD, USA.
- The time-trade off (TTO) approach to measure patients' preferences for health states associated with HPV related pathologies: an Italian multicenter study, Unite For Sight 8th Annual Global Health & Innovation Conference, Yale University, USA, April 16-17, 2011.
- Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers, Plenary Lecture 1, 2nd International Conference on ONCOLOGY: ONCOLOGY'11, 23-25 February 2011, University of Cambridge, Cambridge, UK.
- The time-trade off approach to measure patients' preferences for health states associated with HPV related pathologies: a multicenter study performed in Italy, World Congress of Vaccine-2010, 23-26 March 2010, Beijing, China.
- The time-trade off (TTO) approach to measure patients' preferences for health states associated with HPV related pathologies: a multicenter pilot study performed in Italy, European Conference on Health Economics (ECHE 2010), 7-10 July 2010, Helsinki.
- Governance of preventive health Intervention and On time Verification of its Efficiency in a Region of Southern Italy. The Third Biennial Conference of the American Society of Health Economists (ASHE), June 20-23, 2010, Cornell, USA.
- Bayesian Modelling Assessing the Effectiveness of a Vaccination Strategy to Prevent HPV-Related Diseases: the BEST study. World Meeting and the Ninth Valencia International Meeting on Bayesian Statistics, June 3rd to June 8th, 2010 Valencia, Spain.
- Governance of preventive health Intervention and On time Verification of its Efficiency in a Region of Southern Italy. BIT Life Sciences' 1st World Congress of Virus and Infections-2010 (WCVI-2010). July 31-August 3, 2010, Busan, South Korea.
- DIRECT EXPENSE AND COST PREDICTIVE FACTORS OF INVASIVE CERVICAL CANCER: AN ASSESSMENT BASED ON LONGITUDINAL CROSS-LINKED DATA, 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), 11-14 October 2009, Belgrado.
- The time-trade off approach to measure patients' preferences for health states associated with HPV related pathologies: a multicenter pilot study performed in Italy, 6th Health Technology Assessment International (HTAi) Annual Meeting, 21-24 June 2009, Singapore.
- Anti-HPV Vaccination in Italy: Comparison of Recent Economic Evidences, 7th World Congress on Health Economics, organised by International Health Economics Association (IHEA), Annual Meeting, July 12-15, 2009, Beijing, China.
- The Cervical Cancer Cost Assessment (C3A) Study: A Cross-linking Data-based Analysis Designed to Estimate Direct Expenses Induced by the Management of Early Stage versus Locally Advanced Cervical Cancer in Italy, 6th Health Technology Assessment International (HTAi) Annual Meeting, 21-24 June 2009, Singapore.
- Extending FLU vaccination in individuals aged 50 to 64 years of 4 EU Countries: social savings and Budget Impact Analysis. 6th Health Technology Assessment International (HTAi) Annual Meeting, 21-24 June 2009, Singapore.
- TTO approach and HPV-related pathologies: a multicenter pilot study. The 25th International Papillomavirus Conference May 8-14 2009, Malmö, Sweden.
- La Valutazione Economica per migliorare l'assistenza: il caso delle Cefalee. Relazione invitata al XII Congresso Nazionale della SISC (Società Italiana per lo Studio delle Cefalee), 2-4 Ottobre 2008, Torino.
- Il Vaccino quadrivalente anti-HPV: impatto complessivo delle patologie ed aspetti economici della loro prevenzione. Relazione invitata al 43° Congresso nazionale SItI (Società Italiana di Igiene Medicina Preventiva e Sanità Pubblica), 1-4 Ottobre 2008, Bari.

- Pharmacoeconomics and resource allocation, relazione invitata al Convegno Healthcare Costs in HIV Infections: State of Art and Perspectives, Roma Sept 12, 2008.
- Pharmaco economic model to approach a vaccination program, relazione invitata alla Round Table on Vaccination Policies in Europe – Ensuring timely access to public health interventions for European citizens, organizzato dallo Swedish Institute for Infection Disease Control, Karolinska Institut, Stoccolma 13 giugno 2008.
- Aspetti Economici dell'Ipovisione, relazione invitata al Congresso Nazionale GISI, Facoltà di Medicina Università di Roma Tor Vergata, 23 maggio 2008, Roma.
- Le Valutazioni Economiche nell'Health Technology Assessment, Relazione invitata al 7° Convegno Nazionale "Economia del Farmaco e delle Tecnologie Sanitarie", Milano, 9-10 giugno 2008.
- La Vaccinazione e la Valutazione Economica, relazione invitata alla tavola rotonda del Convegno "Attualità e prospettive delle vaccinazioni", Frascati (Roma) Villa Mondragone 28 maggio 2008.
- Improving care through health economics analyses, Session III: Headache Care: 1. Quality Assessment & Improvement, 17th International headache Research Seminar, march 7-9, 2008, Chicago.
- "Studio per l'estensione della vaccinazione preventiva per l'influenza e le sue complicanze: i risultati di una simulazione", Health Technology Assessment in Italia: Modelli, Strumenti ed Esperienze, Università Cattolica del Sacro Cuore, Roma 8-9 Febbraio 2008.
- "Vaccinazione anti HPV: recenti evidenze economiche a confronto", invited paper presentato al Convegno La prevenzione del carcinoma della cervice uterina. Il ruolo della vaccinazione per la salute della donna: realtà e prospettive future, organizzato da Università degli Studi di Genova e Società Italiana di Igiene Medicina Preventiva e Sanità Pubblica, Genova 31 Gennaio, 1-2 Febbraio 2008.
- "Cost-effectiveness analysis of the implementation of a quadrivalent (types 6, 11, 16 & 18) human papillomavirus vaccine to the existing Italian cervical screening programme". 24th International Papillomavirus Conference and Clinical (IPCC) Workshop, Beijing, China, November 2007.
- "Treatment costs associated with restless legs syndrome in Italy", paper accettato a ISPOR 10th Annual European Congress, Dublino, 20-23 Ottobre 2007.
- "Strategies and performances in the Italian pharmaceutical market. An empirical analysis", paper accettato alla 10th Portuguese Conference on Health Economics, Lisbona 22-24 Novembre 2007.
- "Health expenditure in OECD Countries: an econometric analysis", paper presentato al 6th World Congress on Health Economics, 7-11 luglio, Copenhagen, 2007.
- "L'appropriatezza nella prescrizione dei farmaci: una esperienza locale", (Sanò M., Ratti M., Musumeci V., Pavan R., Didoni G., Mennini F.S), abstract book del Convegno su Valutazione e Customer Satisfaction per la qualità dei servizi, 2007.
- The Evolution of Health Expenditure in Italy and in OECD Countries, invited paper presentato al II Congreso Economía de la Salud de América Latina y el Caribe, organizzata dalla Associazione di Economia Sanitaria dell'America Latina e del Caribe, Buenos Aires 31 Ottobre e 1-2 Novembre 2006..
- "Human cost of disease in Italy", paper accettato alla 6th European Conference on Health Economics, organizzata dalla European Health Economics Association, Budapest July 6-9 2006.
- "The evolution and impact of generics market in Italy", paper accettato alla 6th European Conference on Health Economics, organizzata dalla European Health Economics Association, Budapest July 6-9 2006.
- "Economic evaluation for colorectal cancer screening", paper accettato alla 6th European Conference on Health Economics, organizzata dalla European Health Economics Association, Budapest July 6-9 2006.
- "The Italian pharmaceutical market: a micro analysis", paper accettato alla 1st Conference of the American Society of Health Economics, Madison (USA), June 2006.
- "Dynamics and Regulation of European Pharmaceutical Market", First Annual Conference, Italian Society of Law and Economics, Facoltà di Economia, Università di Siena, 25-27 Novembre 2005.

Scientific Association

- Italian Health Economics Association (AIES)
- Pharmacoeconomics Italian Group (GISF)
- International Health Economics Association (IHEA)
- International Health Policy and Management Institute (IHPMI)
- European Conference on Health Economics (*Chair of the Scientific Committee*)



Prof. Francesco Saverio Mennini

**Research Director
Centre for Economic Evaluation and HTA (EEHTA)**

**Faculty of Economics and Faculty of Science -University of Rome Tor Vergata"
Faculty of Statistics, University of Rome La Sapienza Kingston
University, London, UK**

**Via Columbia 2
00198 Rome - Italy
tel: +39 06 72595642
pers. ph.: +39 333 4991647
Web: <http://www.ceistorvergata.it/area.asp?a=626>**

Tel. University: +39 06 72595642 (direct) – Pers. Ph: +39 333 4991647 - E-Mail: f.mennini@uniroma2.it

CURRICULUM VITAE OF

Alberto Migliore MD

Born in Rome on Jan.19th.1960.

Graduated in Medicine and Surgery at the University of Rome "La Sapienza" on July 21st.1984 with vote 110/110 cum laude discussing the thesis " The clearance of the exogenous lipids in patient affected by liver cirrhoses."

Specialized in Internal Medicine at the third school of the university of Rome on "La Sapienza" July 24th.1989, with the vote of 70/70 cum laude discussing the thesis: "Identification of high risk subjects among the relatives of patients affected by type 1 diabetes."

From 1985 till 1989 he worked at the institute of Internal Medicine of the Catholic University where studied in particular the following items: 1) Prevention of type 1 diabetes; 2) immunotherapy in oncology; 3) Bioethic problems regarding Internal Medicine.

He participated at the course of hospital management at St. Pietro hospital from 11.13.1989 to 4.9.1990 for a total of 295 lessons passing the final examination with the vote of 67,1/70.

From 5.15.1990 he works at the St. Pietro hospital in Rome in the Department of Internal Medicine. At now he is the chief of the Rheumatology Unit of this Hospital .

Fields of interest:

- 1) osteoarthritis;
- 2) intra-articular therapy
- 3) Probabilistic metanalysis.

He is the President of "Associazione Nazionale per la Terapia Intra-articolare dell'Anca con Guida Ecografica ANTIAGE- ONLUS". It is the first national association on ultrasound guided intra-articular treatment of rheumatologic disorders affecting the hip in the world. This association also analyses data proceedings from his "National Registry" of all ultrasound guided intra-articular injections of the hip performed in Italy (See website: www.antiagefbf.it).

Since 2006 he works as an Invited Professor of Rheumatology for "Postgraduated school of nursing sciences", University of "La Sapienza", Rome.

Since 12.07.2007 he is member of Advisory Board of the journal "Archives of Orthopaedic and trauma surgery" for three years.

Since November of 2009 he is 'Editor in chief' of the journal 'Topics of Intra-articular Therapy ' published by Verduci Editore. It is sent to 4500 experts among orthopaedics, radiologists, rheumatologists and rehabilitation and sport physicians.

He is member of scientific board of the international " Journal of orthopedics - Translation Research & Clinical Applications" since January 2010

He is the organizer and President of ISIAT (International Symposium on Intra-Articular Therapy), which is an international and interdisciplinary meeting held every two years across Europe.

He also is 'Editor in chief' of "European Journal of musculoskeletal diseases" edited by Biolife.

In the last congress SIR (Italian Society of Rheumatology), he was appointed Secretary General

In June 2012 he published the book " Ultrasound guided intra-articular hip injection: technique and clinical applications" edited by Verduci Editore.

He participated at several national and international congresses presenting lectures, oral communications and posters.

He participated at several clinical studies according to GCP.

He has published more than 100 papers in English, Italian and Spanish

[Incidence and costs of hip fractures vs strokes and acute myocardial infarction in Italy: comparative analysis based on national hospitalization records.](#)

Piscitelli P, Iolascon G, Argentiero A, Chitano G, Neglia C, Marcucci G, Pulimeno M, Benvenuto M, Mundi S, Marzo V, Donati D, Baggiani A, **Migliore A**, Granata M, Gimigliano F, Di Blasio R, Gimigliano A, Renzulli L, Brandi ML, Distante A, Gimigliano R.

Clin Interv Aging. 2012;7:575-83. doi: 10.2147/CIA.S36828. Epub 2012 Dec 17. PMID: 23269863 [PubMed - in process] [Free PMC Article](#)

[Prevalence study of iliopsoas bursitis in a cohort of 860 patients affected by symptomatic hip osteoarthritis.](#)

Tormenta S, Sconfienza LM, Iannessi F, Bizzi E, Massafra U, Orlandi D, **Migliore A**.

Ultrasound Med Biol. 2012 Aug;38(8):1352-6. doi: 10.1016/j.ultrasmedbio.2012.04.006. Epub 2012 Jun 12. PMID: 22698514

[PubMed - indexed for MEDLINE]



[Total hip replacement rate in a cohort of patients affected by symptomatic hip osteoarthritis following intra-articular sodium hyaluronate \(MW 1,500-2,000 kDa\) ORTOBRIX study.](#)

Migliore A, Bella A, Bisignani M, Calderaro M, De Amicis D, Logroscino G, Mariottini F, Moreschini O, Massafra U, Bizzi E, Laganà B, Piscitelli P, Tormenta S. Clin Rheumatol. 2012 Aug;31(8):1187-96. doi: 10.1007/s10067-012-1994-4. Epub 2012 Jun 8. PMID: 22678146

[PubMed - indexed for MEDLINE]

[May etanercept and PTH \(1-34\) association heal erosions in early rheumatoid arthritis? A pilot study.](#)

Migliore A, Massafra U, Bizzi E, Argento G, Diamanti AP, Germano V, Tormenta S, Arduini F, Iannessi F, Granatas M, Laganà B. Eur Rev Med Pharmacol Sci. 2012 Mar;16(3):363-9.

1. [Socioeconomic burden of total joint arthroplasty for symptomatic hip and knee osteoarthritis in the Italian population: A 5-year analysis based on hospitalization records.](#) Piscitelli P, Iolascon G, Di Tanna G, Bizzi E, Chitano G, Argentiero A, Neglia C, Giolli L, Distante A, Gimigliano R, Brandi ML, **Migliore A**. Arthritis Care Res (Hoboken). 2012 Apr 17. doi: 10.1002/acr.21706. [Epub ahead of print]
2. [Can the association of ciclosporine a and methotrexate maintain remission/low disease activity induced by etanercept in early rheumatoid arthritis patients? evaluation by magnetic resonance imaging.](#) Picchianti Diamanti A, Argento G, Podest X00e0 E, Germano V, Fazi S, **Migliore A**, David V, D X0027 Amelio R, Lagan X00e0 B. Int J Immunopathol Pharmacol. 2012 Jan;25(1):301-305.
3. [APPROACH IN GLUCOCORTICOID INDUCED OSTEOPOROSIS \(GIO\) PREVENTION: RESULTS FROM THE ITALIAN MULTICENTER OBSERVATIONAL EGEO STUDY.](#) Massafra U, Migliaccio S, Bancheri C, Chiacchiararelli F, Fantini F, Leoni F, Martin LS, **Migliore A**, Muccifora B, Napolitano C, Pastore R, Ragno A, Ronzoni S, Rotondi M, Tibaldi M, Villa P, Vinicola V, D'Erasmo E, Falaschi P, Minisola G. J Endocrinol Invest. 2012 Mar 6.
4. [Indirect comparison of the effects of anti-TNF biological agents in patients with Ankylosing Spondylitis by means of a Mixed Treatment Comparison performed on efficacy data from](#)

- [published randomised, controlled trials.](#) **Migliore A**, Broccoli S, Bizzi E, Laganà B. *J Med Econ.* 2012;15(3):473-80. Epub 2012 Feb 16.
5. [Mixed-treatment comparison of anabolic \(teriparatide and PTH 1-84\) therapies in women with severe osteoporosis.](#) **Migliore A**, Broccoli S, Massafra U, Bizzi E, Frediani B. *Curr Med Res Opin.* 2012 Mar;28(3):467-73. Epub 2012 Feb 16.
 6. [Interstitial lung disease in rheumatoid arthritis in the era of biologics.](#) Picchianti Diamanti A, Germano V, Bizzi E, Laganà B, **Migliore A**. *Pulm Med.* 2011;2011:931342. Epub 2011 Dec 20.
 7. [The impact of treatment with hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: A retrospective study.](#) **Migliore A**, Bizzi E, Massafra U, Bella A, Piscitelli P, Laganà B, Tormenta S. *Curr Med Res Opin.* 2011 Nov 30. [Epub ahead of print]
 8. [Cyclosporine A in the long-term management of systemic lupus erythematosus.](#) Germano V, Picchianti Diamanti A, Ferlito C, Podestà E, Salemi S, **Migliore A**, D' Amelio R, Laganà B. *J Biol Regul Homeost Agents.* 2011 Jul-Sep;25(3):397-403.
 9. [Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.](#) **Migliore A**, Bizzi E, Broccoli S, Laganà B. *Clin Rheumatol.* 2012 Jan;31(1):133-7. Epub 2011 Jun 24.
 10. [Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis \(ISSO\).](#) Adami S, Maugeri D, Toscano V, Monti S, Vottari S, Topa G, Malavolta N, Buffa A, Brancati A, Massarotti M, Osella G, Iolascon G, Cagnoni C, Camozzi V, Verdoia C, Corradini C, Nardi A, Ulivieri FM, Resmini G, Isaia G, Bevilacqua M, Ortolani S, Pietrogrande L, Rubinacci A, Giannini S, Lo Cascio V, Lacorte R, Massari L, Marcocci C, Di Munno O, Matucci-Cerinic M, Bianchi G, Filipponi P, Mannarino E, Migliaccio S, Spera G, Fornari R, **Migliore A**, Pola E, Costanzo G, De Marinis L, Di Matteo L, Lombardi G, Altomonte L, Silveri F, Cantatore FP, Scillitani A, Muratore M, Russo E, Salomone S, Barbagallo M, Previti B, Velluti C, Tranquilli Leali P, De Giorgi G, Vinicola V, Vedova D, Frisina N, Stisi S, Gallo A, Bardoscia A. *Clin Exp Rheumatol.* 2011 May-Jun;29(3):477-84. Epub 2011 Jun 29. Erratum in: *Clin Exp Rheumatol.* 2011
 11. [A new chance to maintain remission induced by anti-TNF agents in rheumatoid arthritis patients: CYNAR study II of a 12-month follow-up.](#) **Migliore A**, Bizzi E, Massafra U, Vacca F, Martin Martin LS, Ferlito C, Podesta E, Granata M, Lagana B. *Int J Immunopathol Pharmacol.* 2011 Jan-Mar;24(1):167-74.
 12. [Hip viscosupplementation under ultra-sound guidance reduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data from Italian registry.](#) **Migliore A**, Granata M, Tormenta S, Laganà B, Piscitelli P, Bizzi E, Massafra U, Alimonti A, Maggi C, De Chiara R, Iannesi F, Sanfilippo A, Sotera R, Scapato P, Carducci S, Persod P, Denaro S, Camminiti M, Pagano MG, Bagnato G, Iolascon G. *Eur Rev Med Pharmacol Sci.* 2011 Jan;15(1):25-34.
 13. [Hylan g-f 20: review of its safety and efficacy in the management of joint pain in osteoarthritis.](#) **Migliore A**, Giovannangeli F, Granata M, Laganà B. *Clin Med Insights Arthritis Musculoskelet Disord.* 2010 Sep 20;3:55-68.
 14. [Comparison of the Recent-Onset Arthritis Disability questionnaire with the Health Assessment Questionnaire disability index in patients with rheumatoid arthritis.](#) Salaffi F, Ciapetti A, Gasparini S, **Migliore A**, Scarpellini M, Corsaro SM, Laganà B, Mozzani F, Varcasia G, Pusceddu M, Castriotta M, Serale F, Maier A, Foti R, Scarpa R, Bombardieri S; NEW INDICES Study Group. *Clin Exp Rheumatol.* 2010 Nov-Dec;28(6):855-65. Epub 2011 Jan 3.

15. [Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? \(Cynar pilot study\).](#) **Migliore A**, Bizzi E, Massafra U, Vacca F, Martin Martin LS, Ferlito C, Podestà E, Granata M, Laganà B. *Int J Immunopathol Pharmacol*. 2010 Jul-Sep;23(3):783-90.
16. [Viscosupplementation in the management of ankle osteoarthritis: a review.](#) **Migliore A**, Giovannangeli F, Bizzi E, Massafra U, Alimonti A, Laganà B, Diamanti Picchianti A, Germano V, Granata M, Piscitelli P. *Arch Orthop Trauma Surg*. 2011 Jan;131(1):139-47. Epub 2010 Aug 10. Review.
17. [The occurrence of acute myocardial infarction in Italy: a five-year analysis of hospital discharge records.](#) Piscitelli P, Iolascon G, Greco M, Marinelli A, Gimigliano F, Gimigliano R, Gisonni P, Giordano A, **Migliore A**, Granata M, Tarantino U, Brandi ML, Baggiani A, Distante A. *Aging Clin Exp Res*. 2011 Feb;23(1):49-54. Epub 2010 Jul 21.
18. [\[Incidence and socioeconomic burden of hip fractures in Italy: extension study 2003-2005\].](#) Piscitelli P, Brandi ML, Tarantino U, Baggiani A, Distante A, Muratore M, Grattagliano V, **Migliore A**, Granata M, Guglielmi G, Gimigliano R, Iolascon G. *Reumatismo*. 2010 Apr-Jun;62(2):113-8. Italian.
19. [A new technical contribution for ultrasound-guided injections of sacro-iliac joints.](#) **Migliore A**, Bizzi E, Massafra U, Vacca F, Martin-Martin LS, Granata M, Tormenta S. *Eur Rev Med Pharmacol Sci*. 2010 May;14(5):465-9.
20. [Psychometric properties of an index of three patient reported outcome \(PRO\) measures, termed the CLinical ARthritis Activity \(PRO-CLARA\) in patients with rheumatoid arthritis. The NEW INDICES study.](#) Salaffi F, **Migliore A**, Scarpellini M, Corsaro SM, Laganà B, Mozzani F, Varcasia G, Pusceddu M, Pomponio G, Romeo N, Maier A, Foti R, Scarpa R, Gasparini S, Bombardieri S. *Clin Exp Rheumatol*. 2010 Mar-Apr;28(2):186-200. Epub 2010 May 13.
21. [Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept.](#) Picchianti-Diamanti A, Germano V, Ferlito C, **Migliore A**, D'Amelio R, Laganà B. *Qual Life Res*. 2010 Aug;19(6):821-6. Epub 2010 Apr 6.
22. [Viscosupplementation: a suitable option for hip osteoarthritis in young adults.](#) **Migliore A**, Bizzi E, Massafra U, Vacca F, Alimonti A, Iannessi F, Tormenta S. *Eur Rev Med Pharmacol Sci*. 2009 Nov-Dec;13(6):465-72.
23. [Mixed panniculitis responding to cyclosporin-A with a 12-month follow-up: a case report.](#) **Migliore A**, Bizzi E, Santacroce CM, Tarquini E, Massafra U, Vacca F, Martin Martin LS. *Int J Immunopathol Pharmacol*. 2009 Oct-Dec;22(4):1143-6.
24. [Pharmaco-economic issues in the treatment of severe osteoporosis.](#) Piscitelli P, Chitano G, Greco M, Benvenuto M, Sbenaglia E, Coli G, **Migliore A**, Granata M, Iolascon G, Gimigliano R, Baggiani A, Distante A, Tarantino U, Rizzuti C, Brandi ML. *Clin Cases Miner Bone Metab*. 2010 Jan;7(1):61-4.
25. [High serum levels of TNF- \$\alpha\$ and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients.](#) Pavese I, Satta F, Todi F, Di Palma M, Piergrossi P, **Migliore A**, Piselli P, Borghesi R, Mancino G, Brunetti E, Alimonti A. *Ann Oncol*. 2010 Jul;21(7):1523-8. Epub 2009 Dec 23.
26. [Comparative, double-blind, controlled study of intra-articular hyaluronic acid \(Hyalubrix\) injections versus local anesthetic in osteoarthritis of the hip.](#) **Migliore A**, Massafra U, Bizzi E, Vacca F, Martin-Martin S, Granata M, Alimonti A, Tormenta S. *Arthritis Res Ther*. 2009;11(6):R183. Epub 2009 Dec 9.
27. [Comparison of the performance of hip implants with data from different arthroplasty registers.](#) **Migliore A**, Perrini MR, Romanini E, Fella D, Cavallo A, Cerbo M, Jefferson T.J. *Bone Joint Surg Br*. 2009 Dec;91(12):1545-9. Review.

28. [Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey \(RIVIERA study\).](#) Scarpato S, Antivalle M, Favalli EG, Nacci F, Frigelli S, Bartoli F, Bazzichi L, Minisola G, Matucci Cerinic M; RIVIERA co-authors. [Salvarani C, Altucci P, Bombardieri S, Battaglia E, Ferri C, Pozzi MR, Afeltra A, Bersi M, Tartarelli G, Montecucco CM, Altomare E, Bambara LM, Bucci R, Colombelli PL, Corsaro S, Rinaldi F, Sinigaglia L, Trotta F, Carrabba M, Migliore A, Bianchi G, Grassi W, Rocchetta PA, Altomonte L, Coaccioli S, Danieli-Armando G, Perpignano G, Brogginì M, Morassi P, Peronato G, Canesi B, Delsante G, Di Giuseppe P, Di Rosa SO, Gorla R, Malavolta N, Solinas F, Todesco S, Varcasia G, Versace F, Sabadini L, Del Giacco S, Marasini B, Bagnato G, Gerli R, Modena V, Di Piazza V.](#) Rheumatology (Oxford). 2010 Feb;49(2):289-94. Epub 2009 Nov 17.

29. [Hip fractures in Italy: 2000-2005 extension study.](#) Piscitelli P, Gimigliano F, Gatto S, Marinelli A, Gimigliano A, Marinelli P, Chitano G, Greco M, Di Paola L, Sbenaglia E, Benvenuto M, Muratore M, Quarta E, Calcagnile F, Coli G, Borgia O, Forcina B, Fitto F, Giordano A, Distante A, Rossini M, Angeli A, **Migliore A**, Guglielmi G, Guida G, Brandi ML, Gimigliano R, Iolascon G. Osteoporos Int. 2010 Aug;21(8):1323-30. Epub 2009 Oct 7.
30. [Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?](#) Manna R, Verrecchia E, Fonnesu C, Giovinale M, De Socio G, Curigliano V, Cerquaglia C, Soriano A, Granata M, **Migliore A**, Massafra U, Gasbarrini G. Eur Rev Med Pharmacol Sci. 2009 Mar;13 Suppl 1:63-9.
31. [Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption.](#) Laganà B, Picchianti Diamanti A, Ferlito C, Germano V, **Migliore A**, Cremona A, Argento G, David V, Salemi S, D'Amelio R. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):447-54.
32. [The safety of anti-TNF agents in the elderly.](#) **Migliore A**, Bizzi E, Laganà B, Altomonte L, Zaccari G, Granata M, Canzoni M, Marasini B, Massarotti M, Massafra U, Ranieri M, Pilla R, Martin LS, Pezza M, Vacca F, Galluccio A. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):415-26.
33. [Health Technology Assessment: managing the introduction and use of medical devices in clinical practice in Italy.](#) **Migliore A**, Ratti M, Cerbo M, Jefferson T. Expert Rev Med Devices. 2009 May;6(3):251-7. Review.
34. [Intra-articular use of hyaluronic acid in the treatment of osteoarthritis.](#) **Migliore A**, Granata M. Clin Interv Aging. 2008;3(2):365-9. Review.
35. [Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report.](#) **Migliore A**, Signore A, Capuano A, Bizzi E, Massafra U, Vacca E, Todino V, Chianelli M. Eur Rev Med Pharmacol Sci. 2008 Mar-Apr;12(2):127-30.
36. [Bicompartmental device for dynamic cell coculture: design, realisation and preliminary results.](#) Ciofani G, **Migliore A**, Raffa V, Menciasci A, Dario P. J Biosci Bioeng. 2008 May;105(5):536-44.
37. [Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice.](#) **Migliore A**, Tormenta S, Massafra U, Bizzi E, Iannesi F, Alimonti A, Granata M. Curr Med Res Opin. 2008 May;24(5):1309-16. Epub 2008 Mar 27.
38. [Combined use of teriparatide and TNFalpha blockade: safety.](#) **Migliore A**, Massafra U, Capuano A, Martin SM. Aging Clin Exp Res. 2007 Jun;19(3 Suppl):18-20.

39. [Multiple chemical sensitivity syndrome in Sjögren's syndrome patients: casual association or related diseases?](#) **Migliore A**, Bizzi E, Massafra U, Capuano A, Martin Martin LS. Arch Environ Occup Health. 2006 Nov-Dec;61(6):285-7.
40. [\[Correlation between radiologic and ultrasonographic patterns and clinical manifestations in symptomatic hip osteoarthritis\].](#) **Migliore A**, Tormenta S, Iannessi F, Mascheroni E, Barbati E, Capuano A, Diaco M, Massafra U, Padalino C, Vacca F, Alimonti A, Martin LS, Granata Reumatismo. 2007 Jan-Mar;59(1):57-65. Italian.
41. [\[18-month observational study on efficacy of intraarticular hyaluronic acid \(Hylan G-F 20\) injections under ultrasound guidance in hip osteoarthritis\].](#) **Migliore A**, Tormenta S, Massafra U, Martin Martin LS, Carloni E, Padalino C, Alimonti A, Granata M. Reumatismo. 2006 Jan-Mar;58(1):39-49. Italian.
42. [TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report.](#) **Migliore A**, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F, Dibiasi N, Alimonti A, Granata M. Eur Rev Med Pharmacol Sci. 2005 Nov-Dec;9(6):373-8.
43. [The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up.](#) **Migliore A**, Tormenta S, Martin Martin LS, Iannessi F, Massafra U, Carloni E, Monno D, Alimonti A, Granata M. Clin Rheumatol. 2006 May;25(3):389-93. Epub 2005 Oct 25.
44. [Repeated ultrasound-guided intra-articular injections of 40 mg of Hyalgan may be useful in symptomatic relief of hip osteoarthritis.](#) **Migliore A**, Tormenta S, Massafra U, Carloni E, Padalino C, Iannessi F, Alimonti A, Martin LS, Granata M. Osteoarthritis Cartilage. 2005 Dec;13(12):1126-7.
45. [\[Intra-articular treatment with Hylan G-F 20 under ultrasound guidance in hip osteoarthritis. Clinical results after 12 months follow-up\].](#) **Migliore A**, Tormenta S, Valente C, Massafra U, Martin Martin LS, Carmenini E, Bernardini A, Alimonti A. Reumatismo. 2005 Jan-Mar;57(1):36-43. Italian.
46. [Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 \(Synvisc\) in the treatment of symptomatic hip osteoarthritis.](#) **Migliore A**, Tormenta S, Martin LS, Valente C, Massafra U, Granata M, Alimonti A. Clin Rheumatol. 2005 Jun;24(3):285-9. Epub 2004 Dec 9.
47. [\[Safety profile of 185 ultrasound-guided intra-articular injections for treatment of rheumatic diseases of the hip\].](#) **Migliore A**, Tormenta S, Martin Martin LS, Valente C, Massafra U, Latini A, Alimonti A. Reumatismo. 2004 Apr-Jun;56(2):104-9. Italian.
48. [Infliximab therapy in patients with secondary Sjögren's syndrome: functional evaluation.](#) Martin Martin LS, **Migliore A**, Todino V, Pagano A, Chianelli M. Clin Exp Rheumatol. 2003 May-Jun;21(3):412. No abstract available.
49. [A new mathematical model based on clinical and laboratory variables for the diagnosis of Sjögren's syndrome.](#) Martin-Martin LS, Latini A, Pagano A, Ragno A, Stasi R, Coppè A, Davoli G, Crescenzi A, Alimonti A, **Migliore A**. Clin Rheumatol. 2003 May;22(2):123-6.
50. [Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip.](#) **Migliore A**, Martin LS, Alimonti A, Valente C, Tormenta S. Osteoarthritis Cartilage. 2003 Apr;11(4):305-6. No abstract available.
51. [Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion.](#) Manna R, **Migliore A**, Martin LS, Ferrara E, Ponte E, Marietti G, Scuderi F, Cristiano G, Ghirlanda G, Gambassi G. Br J Clin Pract. 1992 Autumn;46(3):177-9.
52. [\[Immunogenetic and functional study of first-degree relatives of patients with type I diabetes mellitus for identifying prediabetic subjects\].](#) Manna R, **Migliore A**, Corsello S, De Marinis L, Scuderi F, Martin LS, Rota CA, Barbarino A, Gambassi G. Clin Ter. 1990 Jan 31;132(2):109-15. Italian.

53. [Insulin adsorption to three-liter ethylen vinyl acetate bags during 24-hour infusion](#). Doglietto GB, Bellantone R, Bossola M, Perri V, Ratto C, Pacelli F, Sofo L, **Migliore A**, Manna R, Crucitti F. JPEN J Parenter Enteral Nutr. 1989 Sep-Oct;13(5):539-41.
54. [Diabetic diarrhea and clonidine](#). **Migliore A**, Barone C, Manna R, Greco AV. Ann Intern Med. 1988 Jul 15;109(2):170-1.

.....

ABSTRACTS pubblicati all'EULAR

1. [\[SAT0243\] INTRARTICULAR INJECTIONS OF DIFFERENT PRODUCTS OF HYALURONIC ACID IN SYMPTOMATIC HIP OSTEOARTHRITIS: REPORT FROM 454 PATIENTS AFTER A 12 MONTHS FOLLOW UP](#)

Authors: A. Migliore¹, U. Massafra¹, E. Bizzi¹, F. Vacca¹, E. Mascheroni¹, F. Iannessi¹, A. Alimonti¹, M. Granata², S. Martin Martin³, S. Tormenta⁴

Year: 2007

Session Info: Osteoarthritis clinical aspects and treatment

2. [\[SAT0247\] ULTRASOUND GUIDED INTRA-ARTICULAR ADMINISTRATION OF HYLAN G-F 20 \(SYNVISC®\) IN 223 PATIENTS SUFFERING FROM SYMPTOMATIC HIP OSTEOARTHRITIS](#)

Authors: A. Migliore¹, S. Tormenta², U. Massafra³, F. Iannessi², E. Carloni³, G. Barbati⁴, C. Padalino³, A. Alimonti³, L. Grillo³, M. Granata⁵, A. Ragno⁶, L. Martin martin⁵

Year: 2005

Session Info: Osteoarthritis Clinical aspects and treatment

3. [\[AB0159\] COMPARISON OF THE RECENT-ONSET ARTHRITIS DISABILITY QUESTIONNAIRE WITH THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX IN PATIENTS WITH RHEUMATOID ARTHRITIS](#)

Authors: F. Salaffi¹, A. Ciapetti¹, S. Gasparini¹, A. Migliore², M. Scarpellini³, S.M. Corsaro⁴, B.

Laganà⁵, F. Mozzani⁶, G. Varcasia⁷, M. Pusceddu⁸, M. Castriotta⁹, F. Serale¹⁰, A. Maier¹¹, R. Foti¹², R. Scarpa¹³, S. Bombardieri¹⁴, NEW INDICES Study Group

Year: 2010

Session Info: Rheumatoid arthritis prognosis, predictors and outcome

4. [\[AB0350\] DOES THE CAUSE OF ANTI-TNF ALPHA INTERRUPTION INFLUENCE THE CLINICAL OUTCOME OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT?](#)

Authors: U. Massafra, E. Bizzi, F. Vacca, A. Migliore

Year: 2010

Session Info: Rheumatoid arthritis other biologic treatment

5. [\[THU0293\] REPEATED INTRA-ARTICULAR ADMINISTRATIONS OF HYLAN G-F 20 \(SYNVISC®\) IN 169 PATIENTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE HIP. A 24 MONTH COHORT STUDY](#)

Authors: A. Migliore¹, U. Massafra¹, E. Bizzi¹, S. Martin Martin², A. Alimonti¹, M. Granata³, F. Vacca¹, B. Laganà⁴, M. Massarotti⁵, P. Persod⁶, S. Tormenta⁷

Year: 2008

Session Info: Osteoarthritis Clinical aspects and treatment

6. [\[THU0172\] PSYCHOMETRIC PROPERTIES OF THE SELF-ADMINISTERED CLINICAL ARTHRITIS ACTIVITY \(SELF-CLARA\) IN PATIENTS WITH RHEUMATOID ARTHRITIS. PRELIMINARY DATA ON BEHALF OF THE "NEW INDICES" STUDY GROUP*](#)

Authors: F. Salaffi¹, S. Gasparini¹, G. Varcasia², G. Pomponio³, R. Scarpa⁴, F. Mozzani⁵, A. Maier⁶, N. Romeo⁷, A. Migliore⁸, M. Scarpellini⁹, B. Laganà¹⁰

Year: 2009

Session Info: Rheumatoid arthritis Prognosis, predictors and outcome

7. [\[AB0153\] SAFETY AND EFFICACY OF LONG TERM THERAPY WITH ANTI-TNF ALPHA IN PATIENTS](#)

WITH ANKYLOSING SPONDYLITIS: A CASE REPORT OF 32 MONTH FOLLOW-UP

Authors: A. Migliore¹, U. Massafra², L. Martin Martin³, C. Valente³, S. Bianconi³, L. Giubilei³, A. Alimonti³

Year: 2004

Session Info: Paediatric rheumatology

8. **[AB0286] RATE OF TOTAL HIP REPLACEMENT IN A COHORT OF PATIENTS SUFFERING FROM HIP OSTEOARTHRITIS TREATED WITH INTRA-ARTICULAR SODIUM HYALURONATE (HYALONE, MW 1500-2000 KDA)**

Authors: A. Migliore¹, E. Bizzi¹, U. Massafra¹, M. Calderaro², M. Bisignani³, D. De Amicis⁴, G. Logroscino⁵, F. Mariottini⁶, O. Moreschini⁷, B. Laganà⁸, S. Tormenta⁹

Year: 2011

Session

Info: Osteoarthritis

9. **[SAT0456] ASSESSMENT OF DISEASE ACTIVITY BY 99MTC-EDDA/TRICINE-HYNIC-TYR-OCTREOTIDE SCINTIGRAPHY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SECONDARY SJOGREN SYNDROME BEFORE AND AFTER INFLIXIMAB TREATMENT**

Authors: A. Migliore³, L. Martin Martin¹, A. Ragno¹, T. Rinaldi¹, A. Pagano¹, M. Chianelli², V. Todino², U. Massafra³, M. Diaco³, A. Capuano³, E. Mascheroni³

Year: 2006

Session

Info: Diagnostics and imaging procedures

10. [\[SAT0437\] INFLIXIMAB INDUCES REMISSION OF CLINICAL SYMPTOMS IN DIABETIC AND OSTEOPOROTIC PATIENTS AFFECTED BY POLYMYALGIA RHEUMATICA](#)
Authors: A. Migliore¹, L. Martin martin², U. Massafra³, M. Granata⁴, E. Carloni⁵, C. Padalino⁵, F. Lasaracina⁵, L. Grillo⁵, N. Di biase⁵, A. Alimonti⁵
Year: 2005
Session
Info: Miscellaneous rheumatic diseases
11. [\[OP0017\] DIFFERENT US PATTERNS IN A COHORT OF 490 PATIENTS SUFFERING FROM DIFFERENT DEGREES OF SYMPTOMATIC HIP OSTEOARTHRITIS](#)
Authors: S. Tormenta¹, F. Iannessi¹, U. Massafra², E. Carloni², C. Padalino², A. Alimonti², P. Nardis¹, A. Migliore³
Year: 2005
Session Info: Advances in imaging
12. [\[FRI0134\] SALIVARY GLAND SCINTIGRAPHY REVEALS IMPROVEMENT OF SALIVARY GLANDS FUNCTION IN PATIENTS WITH SJOGREN'S SYNDROME AFTER INFLIXIMAB THERAPY](#)
Authors: L.S. Martin Martin¹, A. Migliore², V. Todino³, A. Pagano¹, A. Ragno¹, E. Cavallaro¹, M. Chianelli²
Year: 2003
Session Info: Sjogren's syndrome
13. [\[FRI0375\] COHORT STUDY OF 753 PATIENTS SUFFERING FROM SYMPTOMATIC HIP OSTEOARTHRITIS TREATED WITH INTRA-ARTICULAR ADMINISTRATION OF HYLAN G-F 20 \(SYNVISC®\)](#)
Authors: A. Migliore¹, M. Diaco¹, U. Massafra¹, E. Mascheroni¹, A. Capuano¹, A. Alimonti¹, S.

Tormenta ², F. Iannessi ², M. Granata ³, G. Barbati ⁴, L. Martin ⁵

Year: 2006

Session Info: Osteoarthritis clinical aspects and treatment

14 [\[AB0472\] RITUXIMAB FOR SJOGREN'S SYNDROME](#)

Authors: L. Martin¹, A. Ragno¹, M. Chianelli², D. Pierangeli¹, A. Silvestri¹, A. Latini¹, D. Facchini¹, V. Todino², A. Migliore³

Year: 2008

Session Info: SLE, Sjögren's and APS Clinical aspects and treatment

15 [\[AB0684\] EFFICACY OF JOINTEX MINI INTRA-ARTICULAR INJECTIONS FOR THE TREATMENT OF CARPO-METACARPAL JOINT OSTEOARTHRITIS](#)

Authors: M. Massarotti¹, F. Uboldi¹, L. Belloli¹, N. Ughi¹, A. Migliore², B. Marasini^{1,3}

Year: 2010

Session Info: Osteoarthritis

16 [\[FRI0387\] INTRA-ARTICULAR ADMINISTRATION OF 2 INJECTIONS OF HYLAN G-F 20 \(SYNVISC®\) IS AS EFFECTIVE AS 3 INJECTIONS IN PAIN RELIEF IN PATIENTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE HIP](#)

Authors: A. Migliore¹, S. Tormenta ², C. Valente ³, U. Massafra ³, L.S. Martin Martin ⁴, D. Monno ⁵, A. Alimonti ³

Year: 2004

Session Info: Osteoarthritis Clinical aspects and treatment

17 [\[SAT0126\] PROSPECTIVE STUDY ON MAINTENANCE OF LOW DISEASE ACTIVITY WITH A-CYCLOSPORIN AND METHOTREXATE IN RHEUMATOID ARTHRITIS AFFECTED PATIENTS AFTER ANTI-TNF THERAPY: PRELIMINARY DATA](#)

Authors: A. Migliore¹, B. Laganà², E. Bizzi¹, U. Massafra¹, F. Vacca¹, L. Martin Martin³

Year: 2009

Session Info: Rheumatoid arthritis Nonbiologic

treatment

18. [\[AB0329\] EFFICACY OF ULTRASOUND GUIDED INTRA-ARTICULAR INJECTION OF INFLIXIMAB IN ENTEROPATHIC SPONDYLOARTHRITIS PATIENT WITH RESISTANT COXITIS: A CASE REPORT](#)

Authors: A. Migliore¹, C. Padalino¹, U. Massafra¹, A. Alimonti¹, G. Zaccari², F. Iannesi³, S. Tormenta³

Year: 2006

Session Info: Spondylarthropathies including psoriatic arthritis

19. [\[FRI0377\] EFFICACY AND SAFETY OF HYALUBRIX® ADMINISTRATION IN HIP OSTEOARTHRITIS: PROSPECTIVE COHORT STUDY](#)

Authors: A. Migliore¹, U. Massafra¹, F. Iannesi², A. Capuano¹, M.L. Diaco¹, E. Mascheroni¹, A. Alimonti¹, G. Granata³, C. Padalino¹, S. Tormenta²

Year: 2006

Session Info: Osteoarthritis clinical aspects and treatment

20. [\[AB0480\] RETROSPECTIVE STUDY ON SURGERY DELAY IN PATIENTS AFFECTED BY SYMPTOMATIC HIP OSTEOARTHRITIS AND PROPOSED FOR HIP REPLACEMENT AFTER INTRA-ARTICULAR TREATMENT WITH HYLAN G-F20](#)

Authors: A. Migliore¹, E. Bizzi¹, U. Massafra¹, F. Vacca¹, F. Iannesi², S. Tormenta²

Year: 2009

Session Info: Osteoarthritis

21. [\[AB0386\] SAFETY OF TERIPARATIDE AND TNF-BLOCKADE COMBINED USE IN PATIENTS AFFECTED BY INFLAMMATORY ARTHRITIS AND SEVERE OSTEOPOROSIS: CLINICAL EXPERIENCE UPON 6 PATIENTS](#)

Authors: A. Migliore¹, U. Massafra¹, A. Capuano¹, E. Mascheroni¹, M. Diaco¹, M. Granata², L. Martin³

Year: 2006

Session Info: Osteoporosis

22. [\[SAT0307\] GLUCOCORTICOID INDUCED OSTEOPOROSIS: PRELIMINARY DATA FROM THE MULTICENTRIC EGEO \(EVALUATION AND EPIDEMIOLOGY OF GLUCOCORTICOID INDUCED OSTEOPOROSIS\) STUDY](#)

Authors: U. Massafra¹, M. Antonelli², M. Marini², V. Vinicola³, A. Migliore⁴, P. Falaschi⁵, E. D'Erasmus⁶, G. Minisola²

Year: 2010

Session Info: Osteoporosis

23. [\[AB0391\] CICLOSPORIN A IN THE LONG-TERM MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS](#)

Authors: V. Germano¹, A. Picchianti Diamanti¹, E. Podesta¹, C. Ferlito¹, A. Cappella¹, A. Migliore², B. Lagana¹

Year: 2010

Session Info: SLE, Sjögren's and APS treatment

24. [\[FRI0376\] STUDY TO COMPARE HYALUBRIX® AND INTRA-ARTICULAR LOCAL ANAESTHETIC IN THE TREATMENT OF SYMPTOMATIC HIP OSTEOARTHRITIS](#)

Authors: A. Migliore¹, U. Massafra¹, A. Capuano¹, E. Mascheroni¹, M.L. Diaco¹, C. Padalino¹, F. Iannesi², S. Tormenta²

Year: 2006

Session Info: Osteoarthritis clinical aspects and treatment

25. [\[AB0422\] SYMPTOMATIC RELIEF AFTER INTRA-ARTICULAR ADMINISTRATION OF HYLAN G-F 20 \(SYNVISC®\) IN PATIENTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE HIP MAY LAST UP TO 6 MONTHS: PRELIMINARY DATA](#)

Authors: A. Migliore¹, C.C. Valente¹, L.S. Martin², A. Alimonti¹, D. Monno³, S. Tormenta⁴

Year: 2003

Session Info: Osteoarthritis Clinical aspects and treatment

26. [\[FRI0092\] INTRA-ARTICULAR USE OF](#)

INFLIXIMAB IN ELDERLY SUBJECTS WITH RHEUMATIC DISEASES COMPLICATED BY SEVERAL COMORBIDITIES

Authors: A. Migliore¹, C. Padalino¹, U. Massafra¹, A. Alimonti¹, D. Monno², F. Iannesi³, S. Tormenta³

Year: 2006

Session Info: Rheumatic arthritis other clinical aspects and comorbidity

27. **[AB0206] TNF-ALPHA BLOCKADE INDUCES CLINICAL REMISSION IN PATIENTS WITH POLYMYALGIA RHEUMATICA ASSOCIATED WITH DIABETES MELLITUS AND/OR OSTEOPOROSIS**

Authors: A. Migliore¹, S.L. Martin Martin², C. Valente³, U. Massafra³, F. Lasaracina³, N. Dibiase³, A. Alimonti³

Year: 2004

Session Info: Miscellaneous rheumatic diseases

28. **[AB0363] PROSPECTIVE STUDY ON MAINTENANCE OF LOW DISEASE ACTIVITY WITH A-CYCLOSPORIN AND METHOTREXATE IN RHEUMATOID ARTHRITIS AFFECTED PATIENTS AFTER ANTI-TNF THERAPY: CYNAR2 STUDY, PRELIMINARY DATA**

Authors: A. Migliore¹, E. Bizzi¹, U. Massafra¹, F. Vacca¹, S. Martin Martin², M. Granata³, C. Ferlito⁴, E. Podestà⁴, B. Laganà⁴

Year: 2010

Session Info: Rheumatoid arthritis non-biologic treatment

29. **[SAT0306] PERSISTENCE AND CAUSE OF DISCONTINUATION IN PTH (1-34) TREATMENT: PRELIMINARY DATA FROM AN EDUCATIONAL AND SUPPORT PROGRAM IN SEVERE OSTEOPOROSIS**

Authors: A. Migliore¹, F. Vacca¹, E. Bizzi¹, U. Massafra¹, A. Alimonti¹, M. Infantino²

Year: 2010

Session Info: Osteoporosis

30. **[AB0648] INTRARTICULAR ADMINISTRATION OF JOINTEX IN A COHORT OF 74 PATIENTS AFFECTED BY SYMPTOMATIC HIP**

**OSTEOARTHRITIS: PRELIMINARY DATA AFTER
THREE AND SIX MONTHS OF FOLLOW-UP**

Authors: A. Migliore¹, U. Massafra¹, E. Bizzi¹, F. Vacca¹, E. Mascheroni¹, F. Iannessi¹, A. Alimenti¹, M. Granata², S. Tormenta³

Year: 2007

Session Info: Osteoarthritis clinical aspects and treatment

**31. [SAT0337] USE OF DRUGS FOR BONE LOSS
PREVENTION IN 808 ITALIAN PATIENTS WITH
RHEUMATOID ARTHRITIS TREATED WITH
GLUCOCORTICOIDS**

Authors: U. Massafra¹, M. Rossini², M.L. Sorgi³, M. Antonelli⁴, M. Marini⁴, S. Caporuscio³, A. Migliore¹, G. Minisola⁴

Year: 2010

Session Info: Osteoporosis

ELENA PAOLA LANATI

PERSONAL DATA

Born: in Broni (PV), July 13th 1974. Single
Legal address: via Carducci 12, 20123 Milano, Italy
Mobile phone: +39 349 6485434, +39 335 5208502
E-mail: Lanati@3psolution.it
Web: <http://www.linkedin.com/in/elenalanati>

WORKING EXPERIENCE

- Since Dec 11 **3P Solution Srl.** Managing Director and owner. 2012 Sales doubled vs 2011. Both owned companies account for around 2 millions € sales. 8 employed people.
- Sep 10-Dec 11 **MA Provider Srl.** Owner, founder and Managing Director. Consultancy firm in market access, born thanks to Regione Lombardia funding for new innovative companies, with a project on new drugs pricing.
- Since Jan 10 **3P Solution, Founder and Owner.** CME Provider, among the first 90 companies with Ministry accreditation
- Since Sep 09 **Amgen Dompè, Milano. Regional Market Access head.**
Direct reports: 4 Regional Affairs Managers, 12 Key account managers. Solid line: Italy Corp. Affairs Director.
- Since Jan 09 **BMS, Roma. Onco-Hematology BU Director.**
Objective: lead current Hematology business (22 millions €) and develop new oncology portfolio; lead corporate sales performance excellence program. Direct reports: 2 PMs, 1 assistant, 3 Sales Managers, 25 Product Specialists. Solid line: Italy GM. Member of EMEA Onco Leadership Team .
- Since Jul 07 **UCB Group, Milan. CNS BU Director (Keppra, Neupro)**
Objective: set up the new CNS BU (2007 value: 39 MM €) after Schwarz integration, and launch Neupro (2008). Fully responsible for sales and marketing with direct reports: 2 Brand Managers, 6 District Managers and 56 Product Specialists, 1 Executive Assistant.
Up-to-date results: 30 people hired, 4 reps promoted to sales managers, new sales structure design (territories, incentive scheme, planning process), Keppra growth rate from 30% (Jan-Jun 07) to 40% (2008). Solid line to Global President CNS Operations, and member of Global CNS LT.
- Since Apr 05 **AstraZeneca, Milano Marketing Manager GI, AZ e Simesa (Nexium, Antra, Axagon, Losec)**
Objective: Esomeprazole relaunch. Direct reports: 4 Senior Product Managers and 2 assistants.
Sales results: from 60 to 103 millions\$ in 2 years.
- Since Apr 04 **Manetti&Roberts, Bolton group Milano- Marketing Manager Intimate Hygiene (I.Roberts, Chilly)**
Objective: Chilly relaunch working on the whole brand strategy (inside and outside Italy). Share results: from 5,2% to 8,9% within 6 months.
- Since Apr 03 **Procter& Gamble, Beauty Care BU, Rome, Italy**
Senior Product Manager Infasil, Personal Care brand (56 MM€ turnover).
- Since Aug 02 **Procter& Gamble, Health& Beauty Care BU**
Vicks and Fixodent Product Manager (47 MM€ turnover). Co-leader of the Euro team for the Vicks cold/flu initiative development and launch. Licensing and Acquisition (L&A) responsible for Italy OTC business and part of Euro L&A OTC team.
- Since Nov 01 **Procter& Gamble, Pharmaceutical Division**
Bone Category Manager (Actonel, Cacit D3, Cacit 1000, for osteoporosis- 27 MM\$ turnover).
- Since May 00 **Procter& Gamble, Pharmaceutical Division**
Neoduplamox Product Manager (Amoxicillin e Clavulanic acid; 8 MM\$ turnover, local brand). I had the opportunity to design and develop in full autonomy the Neoduplamox brand equity, as key strategy to sustain the brand long term growth.
- Since Sep 99 **Procter& Gamble, Pharmaceutical Division, Rome**

My move into the Health Economics and Market Access area was prompted by a growing interest in Health Policy and Economics and a recognition that with the advent of more sophisticated and expensive therapies, coupled with the current economic climate this is a critical time for the industry. I am motivated and enthusiastic about my career and am keen to play a part in bringing new medicines to the public.

EDUCATION

- 2013 University of York, Health Economics Resource Centre, York, UK
PG Certificate (2012-2013), Diploma (2013-2014) and MSc (2014- 2015) in Health in Economic Evaluation for Health Technology Assessment (Distance Learning Program)
- 2013 University of York, Health Economics Resource Centre, York, UK
Decision Analytic Modelling for Economic Evaluation (Foundations and Advanced Courses)
- 2012 University for Health Sciences Medical Informatics and Technology, Institute of Public Health, Hall in Tyrol, Austria
Post Graduate Certificate in Clinical Epidemiology
- 2012 University of Aberdeen, Health Economics Research Unit, Aberdeen, UK
Post Graduate Certificate in Health Economics (2011 – 2012)
- 2012 International Society for Pharmacoeconomics and Outcomes Research, ISPOR
Short Courses in: 1) Introduction to health technology assessment 2) Network meta-analysis in relative effectiveness research 3) Introduction to retrospective database analysis 4) Advanced retrospective database analysis 5) Bayesian methods in economic evaluations – introduction 6) Introduction to Modelling 7) Pharmacoeconomic modelling –application
- 2011 Vienna School of Clinical Research, Vienna, Austria
Post Graduate Certificate in Health Outcomes Research
- 2009 Galassia Reti, Running srl, Rome - Brussels, Italy - Belgium
Post Graduate Certificate in European Public Affairs
- 2008 University of Genoa, Faculty of Pharmacy, Genoa, Italy
Master Degree in Pharmacy
Research Thesis at the University of Paris 5, Paris, France (1 year ERASMUS program)

PROFESSIONAL EXPERIENCE

- 2013 Eli Lilly and Company, Global Health Outcomes – Rome, Italy
Outcomes Liaison Manager, Italian Market – Current position (from 03/2011)
- Market Access for diabetes, biomedicine and oncology products (providing clinical, health economics and health outcomes research solutions for value message development)
 - Public Affairs (i.e. Providing clinical, pharmacoeconomic, health outcomes, and health policy information to Value-based Decision Makers)
 - Assisting Lilly in understanding the payer perspective about value assessments, health policy, and evidence-based medicine, for both current and early phase products, thereby informing the medical research agenda
 - Conducting and/or partnering with Value-based Decision Makers and/or their respective organizations on external research collaborations including Global Health Outcomes analytic tools, budget impact models, other kind of economic evaluations and administrative databases analysis
 - Supporting medical business personnel (i.e. Medical Liaisons, Clinical Research functions) and non-medical business personnel (Key and Regional Account Managers, Market Access Managers, Corporate and Public Affairs functions) with comprehensive pharmacoeconomic and health outcomes research education
 - Involvement in other activities such as pharmacy formulary presentations and exhibit booth support
 - Responsible for the implementation of this new role outside US starting with the Italian affiliate. Therapeutic areas of expertise: Diabetes, Osteoporosis, Major Depressive Disorder and Oncology



Tomaso Piaggio

Key Skills

- Organization and prioritization skills
- Numerical and analytical skills
- Strategic thinking
- Accuracy and attention to details
- Ability to collect, process and analyze large amounts of data under tight deadlines
- Tolerant and flexible to different situations
- Leadership & communication skills
- Highly skilled in networking and maintaining professional and personal contacts
- High level of self-motivation and high learning aptitude
- Experience in multicultural, multi-professional teams
- Showing ability to 'go beyond the numbers' and provide informed interpretations and recommendations

Nationality

Italian

Date of birth

13 August 1981

Address

Via della Balduina 174,
00136, Rome
Italy

Mobile: +393294233576

Personal E-mail:

tomaso.piaggio@hotmail.it

- 2011 European Association of Euro-Pharmaceutical Companies – Brussels, Belgium
Administration and Regulatory Manager – (07/2010 – 04/2011)
- Representing Europe's licensed parallel distribution industry and presenting health economics information at the external meetings with MEPs, European Commission's officials and other decision makers
 - Monitoring EU legislation related to parallel trade, health systems and pricing and reimbursement.
 - Supporting and co-ordinating the regulatory affairs, legal and pricing working groups
 - Conducting analysis and reports on price and competition of pharmaceuticals within EU.
 - Identifying and maintaining regular contacts with European Institutions, think-tanks, patient organizations, NGOs and other bodies
- 2010 Propharma Medical Supplies – Abu Dhabi, United Arabs Emirates
International Sales and Marketing Manager – (07/2009 – 06/2010)
- UAE's licensed wholesaler specialized in supplying medicines in the middle-east
 - Sourcing and procuring medicines from EU
 - Provide relevant data, analyses and reports on EU pricing
 - Establishing and maintaining current and potential clients relationships
 - Planning and implementing new business prospects such as differentiation of the portfolio of products of the company and the entry into new business areas
- 2009 Pharmaceutical Group of the European Union - Brussels, Belgium
Public Affairs Officer – (08/2008 – 07/2009)
- Accredited Lobbyist to the European Parliament with the following tasks: lobby and partnership development with different European Institutions and Associations
 - Press monitoring, analysis and investigation in pharmacy related topics
 - Pharmaceutical market analysis and studies (i.e. Pricing systems in EU)
 - Contributing to PGEU internal meetings and representing PGEU at external events and conferences
- 2010 European Pharmaceutical Students' Association - Brussels, Belgium
EPSA President (06/2009 – 06/2010)
- Representing 120.000 pharmacy students from 33 European countries.
 - In charge of team management (8 direct report and 38 people in total)
 - Partnership development with pharmaceutical professionals' associations and pharmaceutical companies, representing EPSA at external events and conferences.
 - Chairing the Annual Congress, Autumn Assembly and Annual Reception
- 2009 European Pharmaceutical Students' Association - Brussels, Belgium
EPSA VP of External Affairs (06/2008 – 06/2009)
- Representing the association in front of the European institutions
 - Being the center of the official EPSA information, creating internal and external communications plans
 - Maintaining the relationship with partners (companies, other associations)
 - Organizing the Annual Reception in the European Parliament
- 2008 Université Paris R. Descartes, Paris, France
Research Fellow (07/2007 – 06/2008)
- Research Project: "Kinetic study of β -Amyloid precursor protein accumulation following diffuse axonal injury in a mouse model of traumatic brain injury: Effects of minocycline and tacrolimus treatments"

LANGUAGES

ITALIAN: Mother Tongue, ENGLISH: Fluent, FRENCH: Fluent

PERSONAL COMPUTER SKILLS

Excellent: Word, Excel, Outlook, Power Point
 Beginner: Treeage

PUBLICATION

Blockade of Acute Microglial Activation by Minocycline Promotes Neuroprotection and Reduces Locomotor Hyperactivity after Closed Head Injury in Mice: A Twelve-Week Follow-Up Study (Journal of Neurotrauma, Vol 27 Issue 5: May 20, 2010)

ADDITIONAL INFORMATION

- 2011 Lilly Global Health Outcomes award for engagement
- Cosmofarma – Fenagifar award 2010 (Young Pharmacist of the Year)